Synopsis-
MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland to commercialize the biosimilar candidate FYB201 (Ranibizumab) in the entire Middle East and North Africa region.
Ranibizumab, a biosimilar to Novartis’ Lucentis®, is indicated for the ‘wet’ form of age-related macular degeneration (AMD), and other serious eye conditions. For 2020, IQVIA reported global sales of USD 4.0 billion, and USD 43 million in MENA.
Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.
MS Pharma and Bioeq Sign Deal for Ranibizumab in MENA.
Bioeq has developed FYB201 in collaboration with its license partner Formycon AG, Germany and will be responsible for the development and supply of the biosimilar. In Europe and the United States, the biosimilar is already under registration by Bioeq and its partners.
Kalle Kaend, CEO, MS Pharma:
“The expansion of our biosimilar portfolio is one of the strategic priorities to support our high growth ambitions and to further strengthen MS Pharma’s leading position in MENA. Ranibizumab, MS Pharma’s third Biosimilar product, is a significant addition and will anchor our Ophthalmology portfolio. The licensing partnership with Bioeq underlines MS Pharma’s commitment to bringing high-quality biosimilar medicines to help improve the lives of patients in MENA.”
Thiemo Schreiber, Vice President Commercial Operations, Bioeq:
“We are proud of having secured MS Pharma as our partner. This agreement is an important milestone in bringing a more affordable treatment option for retinopathies to the people of the MENA region.”
MS Pharma and Bioeq will share revenues from the commercialization of the product. All other financial terms and details of the agreement remain confidential.
Ranibizumab
Mechanism of Action :
Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, a mechanism similar to that of Bevacizumab.
MOA of Ranibizumab
About MS Pharma
MS Pharma is a leading regional pharmaceutical company in the MENA region, well-positioned for fast business growth. Headquartered in Amman, Jordan, and with new management offices in Zug, Switzerland, MS Pharma markets a wide range of generic and biotech products. The company employs over 2400 people in 12 countries.
For more information, please visit www.mspharma.com
About Bioeq
Bioeq AG is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses, and commercializes biosimilars.
For more information, please visit www.bioeq.ch